Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13296 | 0.89 | DPYD (0.59) | DPYDGAAATAD2MAPTALDH1A1 | |
| SCHEMBL6510851 | 0.89 | DPYD (0.47) | DPYDGAAATAD2MAPTALDH1A1 | |
| Thymine SCHEMBL14695416 | 0.81 | ATAD2 (0.66) | DPYDGAAATAD2MAPTALDH1A1 | |
| Pyrimidine SCHEMBL28139051 | 0.78 | DPYD (0.46) | DPYDGAAATAD2MAPTALDH1A1 | |
| Pyridine SCHEMBL28177470 | 0.78 | DPYD (0.46) | DPYDGAAATAD2MAPTALDH1A1 | |
| SCHEMBL4373860 | 0.75 | DPYD (0.41) | DPYDGAAATAD2MAPTALDH1A1 | |
| SCHEMBL309065 | 0.75 | KDM3B (0.43) | DPYD | |
| Eniluracil SCHEMBL9539455 | 0.75 | DPYD (0.65) | DPYDGAAATAD2MAPTALDH1A1 | |
| SCHEMBL14177211 | 0.74 | DPYD (0.59) | DPYDGAAATAD2MAPTALDH1A1 | |
| SCHEMBL1908445 | 0.73 | KMT2A (0.41) | DPYDMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059627-A1 | CRF2 ligands in combination therapy | HO SIEW PENG (US) | 2005-03-17 | — | — | US | claimed |
| EP-1383460-A2 | CRF 2? LIGANDS IN COMBINATION THERAPY | Bristol-Myers Squibb Pharma Company (US) | 2004-01-28 | — | — | EP | claimed |
| US-20020035083-A1 | CRF2 ligands in combination therapy | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-21 | — | — | US | claimed |
| WO-2002005749-A2 | CRF2 LIGANDS IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2000042178-A2 | ANTAGONIST BLOCKADE OF CRF2 RECEPTORS FOR THE TREATMENT OF PSY CHIATRIC DISORDERS AND THE USE OF CHIMERIC ANTISENSE OLIGONUCLEOTIDES IN IN VIVO CNS STUDIES OF GENE FUNCTION | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-07-20 | — | — | WO | claimed |
| US-20050059627-A1 | CRF2 ligands in combination therapy | HO SIEW PENG (US) | 2005-03-17 | — | — | US | disclosed |
| EP-1383460-A2 | CRF 2? LIGANDS IN COMBINATION THERAPY | Bristol-Myers Squibb Pharma Company (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20020035083-A1 | CRF2 ligands in combination therapy | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-03-21 | — | — | US | disclosed |
| WO-2002005749-A2 | CRF2 LIGANDS IN COMBINATION THERAPY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2000042178-A2 | ANTAGONIST BLOCKADE OF CRF2 RECEPTORS FOR THE TREATMENT OF PSY CHIATRIC DISORDERS AND THE USE OF CHIMERIC ANTISENSE OLIGONUCLEOTIDES IN IN VIVO CNS STUDIES OF GENE FUNCTION | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035083-A1 | CRF2 ligands in combination therapy | CRHR2, CRHR1, CRH | DPYD 4635/4885GAA 2341/4885ATAD2 669/4885 |
| US-20050059627-A1 | CRF2 ligands in combination therapy | CRHR2, CRHR1, CRH | DPYD 4661/4885GAA 2260/4885ATAD2 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.